vs
艾伯维（ABBV）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是登士柏西诺德的17.3倍（$16.6B vs $961.0M）。艾伯维净利率更高（10.9% vs -15.2%，领先26.1%）。艾伯维同比增速更快（10.0% vs 6.2%）。艾伯维自由现金流更多（$4.9B vs $60.0M）。过去两年艾伯维的营收复合增速更高（16.2% vs 0.4%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
ABBV vs XRAY — 直观对比
营收规模更大
ABBV
是对方的17.3倍
$961.0M
营收增速更快
ABBV
高出3.9%
6.2%
净利率更高
ABBV
高出26.1%
-15.2%
自由现金流更多
ABBV
多$4.8B
$60.0M
两年增速更快
ABBV
近两年复合增速
0.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $961.0M |
| 净利润 | $1.8B | $-146.0M |
| 毛利率 | 72.6% | 46.1% |
| 营业利润率 | 27.3% | -14.5% |
| 净利率 | 10.9% | -15.2% |
| 营收同比 | 10.0% | 6.2% |
| 净利润同比 | 8354.5% | 66.0% |
| 每股收益（稀释后） | $1.02 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVXRAY
| Q4 25 | $16.6B | $961.0M | ||
| Q3 25 | $15.8B | $904.0M | ||
| Q2 25 | $15.4B | $936.0M | ||
| Q1 25 | $13.3B | $879.0M | ||
| Q4 24 | $15.1B | $905.0M | ||
| Q3 24 | $14.5B | $951.0M | ||
| Q2 24 | $14.5B | $984.0M | ||
| Q1 24 | $12.3B | $953.0M |
净利润ABBVXRAY
| Q4 25 | $1.8B | $-146.0M | ||
| Q3 25 | $186.0M | $-427.0M | ||
| Q2 25 | $938.0M | $-45.0M | ||
| Q1 25 | $1.3B | $20.0M | ||
| Q4 24 | $-22.0M | $-430.0M | ||
| Q3 24 | $1.6B | $-494.0M | ||
| Q2 24 | $1.4B | $-4.0M | ||
| Q1 24 | $1.4B | $18.0M |
毛利率ABBVXRAY
| Q4 25 | 72.6% | 46.1% | ||
| Q3 25 | 66.4% | 48.8% | ||
| Q2 25 | 71.8% | 52.4% | ||
| Q1 25 | 70.0% | 53.0% | ||
| Q4 24 | 70.9% | 49.3% | ||
| Q3 24 | 70.9% | 52.1% | ||
| Q2 24 | 70.9% | 51.9% | ||
| Q1 24 | 66.7% | 53.1% |
营业利润率ABBVXRAY
| Q4 25 | 27.3% | -14.5% | ||
| Q3 25 | 12.1% | -24.1% | ||
| Q2 25 | 31.7% | -13.7% | ||
| Q1 25 | 28.0% | 7.2% | ||
| Q4 24 | -9.9% | -56.2% | ||
| Q3 24 | 26.5% | -48.6% | ||
| Q2 24 | 27.6% | 5.1% | ||
| Q1 24 | 22.7% | 4.4% |
净利率ABBVXRAY
| Q4 25 | 10.9% | -15.2% | ||
| Q3 25 | 1.2% | -47.2% | ||
| Q2 25 | 6.1% | -4.8% | ||
| Q1 25 | 9.6% | 2.3% | ||
| Q4 24 | -0.1% | -47.5% | ||
| Q3 24 | 10.8% | -51.9% | ||
| Q2 24 | 9.5% | -0.4% | ||
| Q1 24 | 11.1% | 1.9% |
每股收益（稀释后）ABBVXRAY
| Q4 25 | $1.02 | $-0.74 | ||
| Q3 25 | $0.10 | $-2.14 | ||
| Q2 25 | $0.52 | $-0.22 | ||
| Q1 25 | $0.72 | $0.10 | ||
| Q4 24 | $-0.03 | $-2.09 | ||
| Q3 24 | $0.88 | $-2.46 | ||
| Q2 24 | $0.77 | $-0.02 | ||
| Q1 24 | $0.77 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $326.0M |
| 总债务越低越好 | $58.9B | $2.3B |
| 股东权益账面价值 | $-3.3B | $1.3B |
| 总资产 | $134.0B | $5.4B |
| 负债/权益比越低杠杆越低 | — | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资ABBVXRAY
| Q4 25 | $5.3B | $326.0M | ||
| Q3 25 | $5.7B | $363.0M | ||
| Q2 25 | $6.5B | $359.0M | ||
| Q1 25 | $5.2B | $398.0M | ||
| Q4 24 | $5.6B | $272.0M | ||
| Q3 24 | $7.3B | $296.0M | ||
| Q2 24 | $13.2B | $279.0M | ||
| Q1 24 | $18.1B | $291.0M |
总债务ABBVXRAY
| Q4 25 | $58.9B | $2.3B | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | $1.7B | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVXRAY
| Q4 25 | $-3.3B | $1.3B | ||
| Q3 25 | $-2.6B | $1.5B | ||
| Q2 25 | $-183.0M | $2.0B | ||
| Q1 25 | $1.4B | $2.0B | ||
| Q4 24 | $3.3B | $1.9B | ||
| Q3 24 | $6.0B | $2.5B | ||
| Q2 24 | $6.8B | $3.1B | ||
| Q1 24 | $8.0B | $3.3B |
总资产ABBVXRAY
| Q4 25 | $134.0B | $5.4B | ||
| Q3 25 | $133.9B | $5.7B | ||
| Q2 25 | $137.2B | $6.1B | ||
| Q1 25 | $136.2B | $6.0B | ||
| Q4 24 | $135.2B | $5.8B | ||
| Q3 24 | $143.4B | $6.6B | ||
| Q2 24 | $141.9B | $6.9B | ||
| Q1 24 | $148.9B | $7.1B |
负债/权益比ABBVXRAY
| Q4 25 | — | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | 0.90× | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $60.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 6.2% |
| 资本支出强度资本支出/营收 | 2.0% | 4.3% |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | $104.0M |
8季度趋势，按日历期对齐
经营现金流ABBVXRAY
| Q4 25 | $5.2B | $101.0M | ||
| Q3 25 | $7.0B | $79.0M | ||
| Q2 25 | $5.2B | $48.0M | ||
| Q1 25 | $1.6B | $7.0M | ||
| Q4 24 | $7.0B | $87.0M | ||
| Q3 24 | $5.4B | $141.0M | ||
| Q2 24 | $2.3B | $208.0M | ||
| Q1 24 | $4.0B | $25.0M |
自由现金流ABBVXRAY
| Q4 25 | $4.9B | $60.0M | ||
| Q3 25 | $6.6B | $40.0M | ||
| Q2 25 | $4.9B | $16.0M | ||
| Q1 25 | $1.4B | $-12.0M | ||
| Q4 24 | $6.8B | $36.0M | ||
| Q3 24 | $5.2B | $98.0M | ||
| Q2 24 | $2.0B | $156.0M | ||
| Q1 24 | $3.8B | $-9.0M |
自由现金流率ABBVXRAY
| Q4 25 | 29.4% | 6.2% | ||
| Q3 25 | 42.1% | 4.4% | ||
| Q2 25 | 31.7% | 1.7% | ||
| Q1 25 | 10.5% | -1.4% | ||
| Q4 24 | 44.7% | 4.0% | ||
| Q3 24 | 35.9% | 10.3% | ||
| Q2 24 | 14.0% | 15.9% | ||
| Q1 24 | 31.3% | -0.9% |
资本支出强度ABBVXRAY
| Q4 25 | 2.0% | 4.3% | ||
| Q3 25 | 2.4% | 4.3% | ||
| Q2 25 | 1.7% | 3.4% | ||
| Q1 25 | 1.8% | 2.2% | ||
| Q4 24 | 1.9% | 5.6% | ||
| Q3 24 | 1.7% | 4.5% | ||
| Q2 24 | 1.7% | 5.3% | ||
| Q1 24 | 1.6% | 3.6% |
现金转化率ABBVXRAY
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | 0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
